4 completed, 1 terminated. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Axelar AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas AXL1717 - Glioblastoma, Gliosarcoma | Phase 1 / Phase 2 | Terminated | Rush University Medical Center | 10 | 2012-12-01 | 2023-05-22 |
| A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors Fasted treatment: AXL1717, Fed treatment: AXL1717 - Solid Tumors, Hematological Malignancies | Phase 1 | Completed | Axelar AB | 13 | 2012-10-01 | 2014-04-07 |
| Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung AXL1717, Docetaxel - Non-small-cell Lung Cancer, Squamous Cell Carcinoma | Phase 2 | Completed | Axelar AB | 100 | 2011-12-01 | 2013-12-05 |
| A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC) AXL1717 - Non Small Cell Lung Cancer | Phase 1 | Completed | Axelar AB | 12 | 2011-01-01 | 2012-11-12 |
| A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer AXL1717 - Solid Tumors | Phase 1 | Completed | Axelar AB | 49 | 2008-04-01 | 2011-09-15 |
Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma of Lung (1) · Astrocytoma (1) · Carcinoma, Squamous Cell (1) · Ependymoma (1) · Glioblastoma (1) · Gliosarcoma (1) · Hematologic Neoplasms (1) · Oligodendroglioma (1)
picropodophyllin (4) · Docetaxel (1)
Sweden (3) · Belarus (1) · Hungary (1) · Poland (1) · Russia (1) · Ukraine (1) · United States (1)
Michael Bergqvist, M.D., Ph.D (1) · Michael Bergqvist, MD (1) · Michael Bergqvist, MD, PhD (1) · Robert Aiken, MD (1) · Simon Ekman, M.D., Ph.D. (1)